NCT02865122View on ClinicalTrials.gov

Safety and Efficacy Study in Infant With SBS

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

March 22, 2018

Study Completion Date

March 22, 2018

Conditions
Short Bowel Syndrome
Interventions
DRUG

NTRA-9620

Oral daily dose

DRUG

Placebo

Oral daily dose

Trial Locations (8)

32610

University of Florida, Gainesville

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital, Cincinnati

64108

Children's Mercy Hospital, Kansas City

77030

Texas Children's Hospital, Houston

94304

Lucile Packard Children's Hospital Stanford, Palo Alto

98105

Seattle Children's Hospital, Seattle

06106

Connecticut Children's Hospital, Hartford

Sponsors

Lead Sponsor

Elgan Pharma Ltd.
All Listed Sponsors
lead

Elgan Pharma Ltd.

INDUSTRY